5 documents found, page 1 of 1
Descriptive analysis of PD-L1 expression in non-small cell lung carcinoma biops...
Estima Fleming, Carolina; Fidalgo, Paula; Miranda, Hugo; Romão, Raquel; Araújo, António; Ramón Vizcaíno, JoséIntroduction: The expression of PD-L1 as a predictive marker of response to treatment of non-small cell lung cancer (NSCLC) allows the identification of patients most likely to benefit from treatment with inhibitors of immune checkpoints. The main objective of this study was to determine the PD-L1 positivity/negativity rates of biopsies diagnosed with NSCLC during the year 2017 and 2018 at CHUPorto and compare ...
Lung Cancer Screening in Portugal: A PULMONALE Pilot Project
Estevinho, Fernanda; Parente, Bárbara; Barata, Fernando; Magalhães, Isabel; França, Manuela; Fidalgo, Paula; Santos, Paulo; Hespanhol, VenceslauN/a.; N/a.
Prognostic value of neutrophil/lymphocyte racio in palliative non-small cell lu...
Romão, Raquel; Miranda, Hugo; Peixoto, Isa; Mendes, Ana Sofia; Azevedo, Sérgio; Fidalgo, Paula; Araújo, AntónioIntroduction: Immune checkpoint inhibitors (IC) are a new therapeutic option for non-small cell lung cancer. A higher neutrophil/lymphocyte ratio has been associated with worse outcomes in patients treated with immune checkpoint inhibitors, lung cancer included. Aim: Study the relation between value of neutrophil/lymphocyte ratio at day one (D1) and day 30 (D30) of treatment, and overall survival (OS) and progr...
Limitations and perceived delays for diagnosis and staging of lung cancer in Po...
Barata, Fernando; Fidalgo, Paula; Figueiredo, Sara; Tonin, Fernanda S.; Duarte-Ramos, FilipaBackground: We aimed to identify the perception of physicians on the limitations and delays for diagnosing, staging and treatment of lung cancer in Portugal. Methods: Portuguese physicians were invited to participate an electronic survey (Feb-Apr-2020). Descriptive statistical analyses were performed, with categorical variables reported as absolute and relative frequencies, and continuous variables with non-nor...
Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in ...
Figueiredo, A.; Almeida, M.A.; Almodovar, M.T.; Alves, P.; A, Araujo; Araújo, D.; Barata, F.; Barradas, L.; Barroso, A.; Brito, U.; Camacho, E.Objective: The main aim of the study was to evaluate the efficacy and safety profile of Nivolumab, an immune-checkpoint-inhibitor antibody, in advanced, previously treated, Non-Small Cell Lung Cancer (NSCLC) patients, in a real world setting. Methods: We performed a retrospective, multicentre data analysis of patients who were included in the Portuguese Nivolumab Expanded Access Program (EAP). Eligibility crite...